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1 INTRODUCTION1 
 
Oral administration is the most popular route due to ease of ingestion, pain 
avoidance, versatility (to accommodate various types of drug candidates), and 
most importantly, patient compliance also, solid oral delivery systems do not 
require sterile conditions and are, therefore, less expensive to manufacture. 
Several novel technologies for oral delivery have recently become available to 
address the physicochemical and pharmacokinetic characteristics of drugs, while 
improving patient compliance. Electrostatic drug deposition and coating, and 
computer assisted three dimensional printing (3DP) tablet manufacture have also 
recently become available. 
Fast dissolving drug delivery systems were first developed in the late 1970s as an 
alternative to tablets, capsules, and syrups for pediatric and geriatric patients who 
experience difficulties in swallowing traditional oral solid dosage forms. The 
novel technology of fast dispersing dosage forms is known as fast dissolve, rapid 
dissolve, rapid melt and quick disintegrating tablets. However, the function and 
concept of all these dosage forms are similar. 
By definition, a solid dosage form that dissolves or disintegrates quickly in the 
oral cavity, resulting in solution or suspension without the need for the 
administration of the water, is known as an oral fast-dispersing dosage form. 
Difficulty in swallowing (dysphagia) is common among all the age groups, 
especially in elderly, and is also seen in swallowing conventional tablets and 
capsules. Dysphagia is associated with many medical conditions, including stroke, 
Parkinson’s, AIDS, thyroidectomy, head and neck thyroid therapy, and other 
neurological disorders, including cerebral palsy. The most common complaint was 
tablet size, followed by surface, form and taste. The problem of swallowing tablet 
was more evident in geriatric and pediatric patients, as well as travelling patients 
who may not have ready access to water. 
1.1 Salient feature of fast dissolving drug delivery system 
1. Ease of administration for patients who are mentally ill disabled and 
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 uncooperative. 
2. Require no water. 
3. Overcomes unacceptable taste of the drugs. 
4. Can be designed to leave minimal or no residue in the mouth after 
 administration and also provide a pleasant mouth feel. 
5. Ability to provide advantages of liquid medication in the form of solid 
 preparation. 
6. Cost effective. 
1.1.1Need for fast dissolving drug delivery systems 
Fast dissolving drug delivery systems can improve acceptance and compliance in 
patients with dysphasia. Similarly, from market point of view, introduction of 
FDDS will assist life cycle management of drug especially if the drug is patent 
protected. 
1.1.2 Dysphasia 
Dysphasia, or difficulty in swallowing, is common all age groups. According to a 
study dysphasia is common in about 35% of the general population, as well as an 
additional 30-40% elderly and 18-20% of all persons in long term care facilities. 
Common complaints about the difficulty in swallowing tablet due to size, surface, 
form and taste of tablets. Geriatric and pediatric patients and travelling patients 
who may not have ready access to water are in the need of easy swallowing of 
dosage forms. These studies show an urgent need for a dosage form like FDDS 
that make tablets disintegrate in the mouth without chewing or additional water 
intake and thus improve patient compliance. 
1.1.3 Market view 
The need for noninvasive delivery systems continues due to poor patient 
compliance with existing delivery regimens, limited market size for drug 
companies and drug uses, coupled with high costs of disease management. 
Pharmaceutical marketing is one reason for the increase in available fast-
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dissolving/disintegrating products. As a drug entity reaches the end of its patent 
life, it is common for pharmaceutical manufacturers to develop a given drug entity 
in a new and improved dosage form. A dosage form allows the manufacturer to 
extend the market exclusivity, while offering its patient population a more 
convenient dosage form or dosing regimen. In this regard, fast 
dissolving/disintegrating formulations are similar to many sustained release 
formulations that are now commonly available. An extension of market 
exclusivity, which can be provided by a fast dissolving/disintegrating dosage 
form, leads to increased revenue, while also targeting underserved and under-
treated patient population. 
1.1.4 Advantages 
These rapid dissolving films offer several advantages like, 
1. Due to the presence of large surface area, films provide rapid  
disintegrating and dissolution in the oral cavity. 
2. Convenient dosing. 
3. Fast disintegration or dissolution followed by quick effect which is  
desirable in some cases such as pain. 
4. Oral dissolving films can be administered without water, anywhere,  
anytime. 
5. Suitability for geriatric and pediatric patients, who experience difficulties  
in swallowing mentally ill, the developmentally disable and the patients 
who are un-cooperative, or are on reduced liquid intake plans. 
6. No risk of choking. 
7. Oral dissolving films are flexible and portable in nature so they provide  
ease in transportation, during consumer handling, storage and enhanced 
stability. 
8. Beneficial in cases such as motion sickness, acute pain, allergic attack or  
coughing, where an ultra rapid onset of action required. 
9. As compared liquid formulations, precision in the administered dose is  
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ensured from each strip of the film. 
10. The oral or buccal mucosa being highly vascularized, drugs can be  
absorbed directly and can enter the systemic circulation without 
undergoing first pass hepatic metabolism. This advantage can be exploited 
in preparing products with improved oral bioavailability of molecules that 
undergo first pass effect. 
11. The sublingual and buccal delivery of a drug via thin film has the potential  
to improve the onset of action, lower the dosing, and enhance the efficacy 
and safety profile of the medicament. 
12. Improved patient compliance. 
13. Life cycle management. 
14. Difficulties caused from swallowing tablets are circumvented, that is  
especially advantageous for pediatric and geriatric patients are in diseases 
with nausea or vomiting. 
1.2 FAST DISSOLVING FILMS2 
Oral films are the newer technologies in the manufacturing of oral disintegrating 
dosage forms. They are thin elegant films of edible water soluble polymers of 
various sizes and shapes like square, rectangle or disc. The stripes may be flexible 
or brittle, opaque or transparent. They are designed to provide rapid disintegration 
on the tongue without the need for the water. Fast disintegrating films (FDF s) 
have a large specific surface area for disintegration. The films alleviate the 
danger/fear of chocking, easy to handle and administer, maintain a simple and 
conventional packing that is east to manufacture thus overcoming the short fails of 
oral fast disintegrating tablets. A major limitation of these dosage forms is low 
drug loading capacity and limited taste masking options. 
Fast disintegrating film is a thin film of 1-10 mm thickness, with area of  
1-20 cm2 of any geometry. Drugs can be incorporated upto a single dose of about 
15 mg. The immediate dissolution in saliva is due to special matrix made from 
water soluble polymers it has usually low tack for easy of handling and 
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application. However, on wetting the wet tack and muco adhesiveness properties 
of the system are designed to secure the film the site of application. Flexibility and 
strength of films are selected to facilitate manufacturing process and process like 
rewinding, die cutting and packing. 
Fast disintegrating film is placed on the patient tongue are mucosal tissue, which 
gets instantly wetted by saliva. The film hydrates rapidly and adheres onto the site 
of application. It then rapidly disintegrates and dissolves to release drug for oral 
mucosal absorption, or for gastric absorption on swallowing. 
Table 1: comparison between oral fast dissolving films and oral 
disintegrating tablets 
Oral dissolving films Oral disintegrating tablets 
It is a film It is a tablet 
Greater dissolution due to large 
surface area 
Lesser dissolution due to less surface 
area 
Better durable than oral disintegrating 
tablets 
Less durable as compared with oral 
films 
More patient compliance Less patient compliance than films 
Low dose can only be incorporated High dose can be incorporated 
No risk of chocking It has a fear of chocking 
 
1.3 FORMULATION CONSIDERATION3 
Active pharmaceutical ingredient 
Film forming polymer 
Plasticizer 
Sweetening agent 
Saliva stimulating agent 
Flavoring agent 
Coloring agent 
1.3.1 Active pharmaceutical ingredient  
A typical composition of the film contains 1-25% w/w of the drug. Variety of 
APIs can be delivered through fast dissolving films. Small dose molecules are the 
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best candidates to be incorporated in OFDFs. Multivitamins upto 10% w/w of dry 
film weight was incorporated in the films with dissolution time of less than 60 
seconds. It is always useful to have micronized API which will improve the 
texture of the film and also for better dissolution and uniformity in the OFDF. 
Many APIs, which are potential candidates for OFDF technology, have bitter 
taste. This makes the formulation unpalatable especially for pediatric preparations. 
Thus before incorporating the API in the OFDF, the taste needs to be masked. 
Various methods can be used to improve the palatability of the formulation. 
1.3.2 Film forming polymers 
The primary use of all thin film oral dosage forms relives on the disintegration in 
the saliva of the oral cavity, the final film that is used must necessarily be water 
soluble. In order to prepare a thin film formulation that is water soluble, excipients 
or polymer must be water soluble with low molecular weight and excellent film 
forming capacity. It should be non-toxic, non-irritant and devoid of leachable 
impurities. It should have good wetting and spread ability property. It should not 
be very expensive and readily available. Microcrystalline cellulose was also used 
to decrease the disintegration time and improve the dissolution of the drug from 
the films. Examples of polymers are 
❖ Guar gum 
❖ Xanthum gum 
❖ Acacia 
❖ Tragacanth 
❖ Polyethylene oxide 
❖ Sodium carboxy methyl cellulose 
❖ Hydroxyl propyl methyl cellulose 
❖ Polyvinyl alcohol 
1.3.3 Plasticizer 
Plasticizer helps to improve the flexibility of the strip and reduces the brittleness 
of the films. The selection of plasticizer will depend upon its compatibility with 
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the polymer and also the type of solvent employed in the casting film. Examples 
of plasticizers are 
❖ Glycerol 
❖ Propylene glycol 
❖ Polyethylene glycol 
❖ Dimethyl phthalate 
❖ Diethyl phthalate 
❖ Dibutyl phthalate 
❖ Triacetin 
❖ Castor oil 
1.3.4 Sweetening agents 
Sweeteners have become the important part of the formulation intented to be 
disintegrated or dissolved in the oral cavity. Generally sweeteners are used in the 
concentration of 3-6% w/w. both natural and artificial sweeteners are used in the 
formulation of these fast dissolving films. Polyhydric alcohols such as such as 
sorbitol, manitol, and isomalt can be used in combination as they additionally 
provide good mouth feel and cooling sensation. However it should be noted that 
they use of natural sugars in such preparation need to be restricted in people who 
all are on diet or in the case of diabetic patents. Due to this reason, the artificial 
sweeteners have gained more popularity in food and pharmaceutical preparations. 
The first generation of the artificial sweeteners are 
❖ Saccharin 
❖ Cyclamate 
❖ Aspartame 
1.3.5 Saliva stimulating agents  
The purpose of using the saliva stimulating agents is to increase the rate of 
production of saliva that would aid in the faster disintegration of the rapid 
dissolving stripes formulations. Generally acids which are used in the preparation 
of food can be utilized as salivary stimulants. Examples are 
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❖ Citric acid 
❖ Malic acid 
❖ Lactic acid 
❖ Ascorbic acid 
❖ Tartaric acid 
These agents are used along are in combination between 2-6 % w/w of the stripes. 
1.3.6 Flavoring agents 
Preferably upto 10 % w/w flavors are added in the OFDF formulations. The 
acceptance of oral disintegrating or dissolving formulation by an individual is 
largely depends on the initial flavor quality which is observed in first few seconds 
after the product has been consumed and the after taste of the formulation which 
lasts for at least about 10 min. The geriatric population like mint or orange flavors 
like fruit punch, raspberry etc. it can be selected from synthetic flavor oils, 
oleoresins peppermint oil, cinnamon oil, spearmint oil, oil of nutmeg are the 
examples of flavor oils while vanilla, cocoa, coffee, chocolate, and citrus are 
fruity flavors. Apple, raspberry, cherry, pineapple are few examples of fruit 
essence type. 
1.3.7 Coloring agents 
FD&C approved coloring agents are used (not exceeding con centration levels of 
1 percent; w/w) in the manufacturing of orally fast dissolving films. Eg titanium 
dioxide. 
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1.4 PROPERTIES OF THE ORAL FILMS4 
Table 2: Properties of the oral films 
PROPERTY 
FLASH 
RELEASE 
MUCOADHESIVE 
MELT RELEASE 
MUCOADHESIVE 
SUSTAINED 
RELEASE 
Area (cm2) 2-8 2-7 2-4 
Thickness 
(µm) 
20-70 50-500 50-250 
Structure 
Film single 
layer 
Single or multilayer 
system 
Multilayer system 
Excipients 
Soluble, highly 
hydrophilic 
polymer 
Soluble, hydrophilic 
polymer 
Low/non soluble 
polymer 
Drug phase Solid solution 
Solid solution/suspends 
drug particle 
Suspension or solid 
solution 
Application 
Tongue (upper 
plate) 
Gingival or buccal 
region 
Gingival (or other 
region of oral cavity) 
Dissolution 
Maximum 
sixty second 
Disintegration in few 
minutes, forming gel 
Maximum 8-10 hours 
Site of action 
Systemic or 
local 
Systemic or local Systemic or local 
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1.5 OVERVIEW OF ORAL MUCOSA5 
The oral mucosa is composed of an outer layer of stratified squamous epithelium. 
Below this lies a basement membrane, a lamina propria followed by the sub 
mucosa as the innermost layer. The epithelium is similar to stratifies squamous 
epethelia found in the rest of the body in that it has a mitotically active basal cell 
layer, advancing through a number of differentiating intermediate layers to the 
superficial layers, where cells are shed from the surface of the epithelium. 
 
Fig 1: Various layers of oral mucosa 
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1.6 METHODS OF PREPARATION OF FAST DISSOLING FILMS6 
One or combination of the following process can be used to manufacture the 
mouth dissolving films. 
1. Solvent casting 
2. Semisolid casting 
3. Hot melt extrusion 
4. Solid dispersion extrusion 
5. Rolling 
1.6.1 Solvent Casting Method 
In solvent casting method water soluble are dissolved in water and the drug along 
with other. Excipients are dissolved in suitable solvent then both the solutions are 
mixed and stirred and finally casted into the petri plate and dried. 
 
Fig 2: Diagram of solvent casting film system 
1.6.2 Semisolid casting 
In semisolid casting method firstly a solution of water soluble film forming 
polymer is prepared. The resulting solution is added to a solution of acid insoluble 
polymer (e.g cellulose acetate phthalate, cellulose acetate butyrate), which was 
prepared in ammonium or sodium hydroxide. Then appropriate amount of 
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plasticizer is added so toast a gel mass is obtained. Finally the gel mass is casted 
into the films or ribbons using heat controlled drums. The thickness of the film is 
about 0.15-0.5 inches. The ratio of the acid insoluble polymer to film forming 
polymer should be 1:4. Both mixtures are mixed to form homogenous viscous 
solution degassed under vaccum. Bubble free solution is coated on non-treated 
casting film coated film is sent to aeration drying oven. Film is cutting into 
desired shape and size. 
1.6.2 Hot melt extrusion 
In hot melt extrusion method firstly the drug is mixed with carriers in solid form. 
Then the extruder having heaters melts the mixture. 
Finally the melt is shaped into films by the dies. There are certain benefits of the 
hot melt extrusion. 
o Fewer operation units 
o Better content uniformity 
o An anhydrous process 
1.6.3 Solid dispersion extrusion 
In this method immiscible components are extruded with drug and then solid 
dispersions were prepared. Finally the solid dispersions are shaped into films by 
means of dies. 
1.6.5Rolling method 
In rolling method a solution or suspension containing drug is rolled on a carrier. 
The solvent is mainly water and mixture of water and alcohol. The film is dried on 
the rollers and cut into desired shapes and sizes.  
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Table 3: Examples of marketed oral thin films 
Brand name 
Manufacturer/ 
distributor 
API (strength) Uses 
Eme film 
Delvin 
formulations pvt 
ltd 
Ondansetron 4 mg 
Nausea & 
vomiting 
Listerine cool 
mint pocket 
packs 
Pfizer Mint crystals Mouth freshner 
Niquistin stripes Omega pharma ltd Nicotine 2.5 mg Anti smoking 
Zupelnz stripes Monosol Rx Ondansetron 8 mg Ondansetron 
Spiromont Monosol Rx Montelukast 10 mg Asthma& allergy 
Sildenafil citrate 
film 
Alpha pharma 
health care 
Sildenafil 50 mg Erectile function 
Tadalafil stripes 
Alpha pharma 
health care 
Sildenafil 20 mg Erectile function 
Vitamin D3 Zim laboratories 
Calciferol  2,000 
I.U 
Calcium 
supplement 
Benadryl 
MC Neil consumer 
health care 
Diphenhydramine 
25 mg 
Antihistamine 
Tri aminic Novartis 12.5 mg Antiallergic 
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1.7 EXCIPIENTS GENERALLY USED IN PREPARATION OF FAST 
DISSOLVING FILMS6 
Table 4: List of excipients 
Ingredients/purpose Examples % (W/W) 
Water soluble polymers 
Cellulose ethers (HPMC, HEC,HPC, and 
MC), PVC, PVA, gelatin, pullulan, 
kollicoat IR, tragacanth gum, guar gum, 
chitin, etc., 
40-50 
Plasticizers Glycerol, PG, PEG 0-20 
Disintegrants 
Pre gelatinised starch, MCC, 
crosspovidone, soluble starch 
0-40 
Preservatives Salts of edetate ( di sodium EDTA) 0.01-1 
Saliva stimulating agent 
Citric acid, lactic, malic, succinic, 
ascorbic, adipic, fumaric and tartaric acid. 
2.5-6 
Cooling agents Mono methyl succinate 0.2-0.4 
Surfactants 
Mono& di glycerides of FA, poly oxy 
ethylene sorbitol esters 
0.5-15 
Stabilizing agents 
Xanthan gum, locust bean gum and 
carrageenan 
0.1-2 
Emulsifying agents 
Triethanolamine stearate, Qt.ammonium 
compounds, acacia, gelatin 
0.01-0.7 
Thickening gents MC, CMC 0.01-5 
Binding agents Starch 0.01-2 
Sweetening agents 
Sucralose, aspartame, acesulfame K, 
neotame 
0-2 
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1.8 EVALUATION OF THE FILMS6 
1.8.1 Thickness 
The film thickness was measured using a micrometer screw gauge at five points 
on the film to ensure the uniformity of the film thickness. The mean thickness was 
calculated from the five points. 
1.8.2 Folding endurance test 
Folding endurance values reflect the strength of the film prepared. 
1.8.3 Weight variation 
Ten films were randomly selected and their average was obtained. Individually 
films were weighed and compared with the average weight for the deviation. 
1.8.4 Drug content 
Drug content determination of the films is to ascertain whether the required 
amount of drug loaded in the polymer or not.  
1.8.5 Disintegration test 
To find out actual time required for disintegration of the film.  
1.8.6 Fourier transform infrared spectroscopy studies(FT-IR) 
FTIR spectral measurements are useful to find out the interaction between the 
polymer, excipients and drug if any. 
1.8.7 Differential scanning calorimeter studies (DSC) 
DSC studies are useful to know the thermal stability of the drug and loaded film. 
1.8.8 In-vitro dissolution test 
Dissolution study was carried out by using a UV spectrophotometer. 
1.8.9 In-vitro disintegration test 
2ml of water was placed in a petriplates with a film on the surface of water. The 
time taken for the disintegration of the film was measured. 
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1.9.0 SEM ANALYSIS 
The morphological study of oral film was done by the scanning electron 
microscopy at definite magnification (SEM). 
1.9 TASTE MASKING TECHNIQUES7 
It is estimated that there are about 10,000 taste buds on the tongue, roof of the 
mouth, cheeks, and throat, and each bud has 60-100 receptor cells. These receptor 
cells interact with molecules dissolved in the saliva and produce a positive or 
negative taste sensation. Many drugs are unpalatable and unattractive in their 
natural state. Physiological and physicochemical approaches have been used to 
prevent drugs from interacting with taste buds, and thus eliminate or reduce 
negative sensory response.  
 
 
Fig 3: Taste buds and neural taste pathways 
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Acids evoke sourness, because H+- receptors in the taste bud. Saltiness is 
produced by the anions of the inorganic salts. The cl- receptor is particularly 
effective in registering saltiness. Our taste buds at the base of the tongue also have 
bitter-receptors stimulated by many long chain organic compounds. Many 
alkaloids (quinine, caffeine, and nicotine) also taste bitter. Sweet receptors are 
stimulated by sucrose, glucose, lactose, maltose, glycerol, alcohol, aldehyde, 
ketones and organic chemicals. FDDFs disintegrating/dissolve in the saliva and 
the drug in FDDFs remain in the oral cavity until it is swallowed. Hence, for a 
drug with bitter taste, taste making becomes critically important in the formulation 
for maximal patient acceptability. Traditional tablet formulations generally do not 
address the issue of taste masking, because it is assumed that the dosage form will 
not dissolve until passing the oral cavity. 
Oral films also called oral wafers in the related literature are a group of flat films, 
which are administered into the oral cavity.   
1.10 APPLICATION OF ORAL STRIP IN DRUG DELIVERY7 
Oral mucosal delivery via buccal, sublingual and mucosal route by the use of 
OTFs could become a preferential delivery method for therapies in which rapid 
absorption is desired, including those used to manage pain, allergies, sleeping 
difficulties and central nervous disorders.  
Dissolvable oral thin films (OTFs) evolved over the fast few years from the 
confection and oral care markers in the form of breath stripes and become a novel 
and widely accepted form by consumers for delivering vitamins and personal care 
products. 
1.10.1 Topical applications 
The use of dissolvable films may be feasible in the delivery of active agents such 
as analgesics or antimicrobial ingredients for wound care other applications. 
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1.10.2 Gastro retentive dosage systems 
Dissolvable films are being considered in dosage forms for which water-soluble 
and poorly soluble molecules of various molecular weights are contained in a film 
format. Dissolution of the films could be triggered by the pH or enzyme secretions 
of the gastrointestinal tract, and could be potentially used to treat gastrointestinal 
disorders. 
1.10.3 Diagnostic devices 
Dissolvable films may be loaded with sensitive reagents to allow control release 
when exposed to a biological fluid or to create isolation barriers for separating 
multiple reagents to enable a timed reaction with a diagnostic device.  
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1.11 DIABETES MELLITUS8, 9 
A group of disease characterized by high levels of blood glucose resulting from 
defects in insulin protection, insulin action or both. 
Diabetes mellitus can be classified into two types, 
 1. Type 1 diabetes 
 2. Type 2 diabetes 
1.11.1 TYPE I DIABETES10, 11 
Type 1 diabetes was previously called insulin dependent diabetes mellitus 
(IDDM) or juvenile-onset diabetes. It develops when the body as immune system 
destroys pancreatic beta cell, the only cells in the body that make the hormone 
insulin that regulates the blood glucose. This form of diabetes usually strikes 
children and young adults, although disease onset can occur at any age. It may 
account for 5-10% of all the diagnosed cases of diabetes. 
Risk factors for type 1 diabetes may include auto immune, genetic and 
environmental factors. 
TREATMENT 
Insulin therapy. 
1.11.2 TYPE II DIABETES12, 13 
Type 2 diabetes was previously called noninsulin dependent diabetes mellitus 
(NIDDM) or adult onset diabetes mellitus. It may account for about 90%-95% of 
all diagnosed cases of diabetes. It usually beings as insulin resistance, a disorder 
in which the cells do not use insulin properly. As the need for insulin rises, the 
pancreas gradually loses its ability to produce insulin. 
Type 2 diabetes associated with old age, obesity, family history of diabetes, 
history of gestational diabetes. Impaired glucose metabolism, physical inactivity, 
and race ethnicity. 
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Type 2 diabetes increasingly being diagnosed in children and adolescence. 
TREATMENT 
Oral hypoglycemic medications. 
Table 5: Oral hypoglycemic agents14 
Drug class Drug name Mechanism of action 
Biquanides   
Sulphonyl urea’s 
(second generation) 
Glimepiride 
Glipizide 
Glyburide 
Increase insulin secretion by 
pancreatic β cells 
 
Mateglitinides 
Rapeglinides 
Nateglinides 
Increase insulin secretion 
Thiozolidinediones 
(TDZs) 
Pioglitazone 
Rosiglitazone 
Increase glucose uptake by 
skeletal muscle 
Alpha glycosidase 
inhibitors 
Agarbose 
Maglitol 
Inhibit carbohydrate absorption in 
the small intestines 
DPP-4 inhibitors Sitagliptin 
Increase insulin secretion by 
pancreatic β cells and suppress the 
release of glucogan by pancreatic 
α cells  
 
Among all the oral hypoglycemic agents for type 2 diabetes mellitus DPP-4 
inhibitors plays an important role in diabetes mellitus. 
Gliptins represent a novel class of agents that improve beta cell health and 
suppress glucogan, resulting in improved post-prandial and fasting hyperglycemia. 
The function by augmenting the cretin system (GLP-1 and GIP) preventing their 
metabolism by Dipeptidyl peptidase -4(DPP-4), are they efficacious and also safe. 
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2. AIM AND OBJECTIVE 
2.1 AIM 
The aim of the present study is to formulate and evaluate the Sitagliptin phosphate 
fast dissolving oral film by using solvent casting method. 
2.2 OBJECTIVE 
 The objective of the proposed work is  
2.2.1 To prepare fast dissolving oral films of Sitagliptin phosphate by using 
different concentrations of film forming polymers and plasticizers. 
2.2.2  The formulations are developed and evaluated for pre-compression 
parameters such as Solubility, Melting point, Heavy metal content, FT-IR 
studies and post-compression parameters such as Weight variation, 
Thickness, Folding endurance, Tensile strength, percentage elongation, 
Drug content, Assay, Disintegration time, dissolution test and SEM 
analysis. 
2.2.3  To improve the patient compliance. 
2.2.4  To get the quick onset of action to relieve the symptoms of hyperglycemia. 
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3. PLAN OF WORK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig4: Plan of Work 
Literature review 
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Evaluation of oral film 
Weight variation, Thickness, Folding endurance , tensile strength, 
percentage elongation, drug content, assay, disintegration time, dissolution 
test, SEM Analysis 
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4. LITREATURE REVIEW 
  
Nishi Thakur et.al2 prepared ‘Overview “A novel approach of fast dissolving 
films and their patients”. Fast dissolving drug delivery systems have started 
gaining fame and acceptance as new drug delivery systems. Which aim to 
enhance safety and efficacy of a drug molecule by formulating it into a 
conventional oral dosage form for administration and to achieve better patient 
compliance. Fast dissolving drug delivery the film is placed on the top or the 
floor of the tongue. When put on the tongue, this film dissolves instantaneously, 
releasing the drug which dissolves in the saliva. Some drugs are absorbed from 
the mouth, pharynx and esophagus as the saliva passes down into the stomach. 
In such case is enhancing drug bioavailability, no risk of chocking, provide good 
mouth feel. Fast dissolving drug delivery system to overcome this problem 
difficulty in swallowing tablets/capsules etc. This review article overview the 
advancement in the oral dosage forms application, formulation consideration, 
method of preparation, evaluation, marketed product and patented technologies 
of oral fast disintegrating films. 
Arun arya et.al5 were reviewed ‘Fast dissolving oral films: An innovative drug 
delivery system and dosage form’. Dissolvable oral thin films (OTFs) evolved 
over the past years from the confection and oral care markets in the form of 
breath strips and become a novel and widely accepted from by consumers for 
delivering vitamins and personal care products. Companies with experience in 
the formulation of polymer coatings containing active pharmaceutical 
ingredients (APIs) for transdermal drug delivery capitalized on the opportunity 
to transition technology to ODF formats 
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G. Kadhe and R.E. Arasan et.al8 studied as attempt to describe the advances 
drug delivery of oral hypoglycemic agents, particularly the immediate release 
formulations of sitagliptin phosphate. 
Shelen M colham et.al9 studied The primary prevention of cardiovascular 
disease with atorvastatin in type 2 diabetes in the collaborative Atorvastatin 
diabetes study. 
Jigisha patel et.al10 studied the Dyslipidaemia in diabetes mellitus. The study 
revealed that statics improved cardiovascular out comes in people with diabetes 
mellitus. Atorvastatin 10mg daily significantly reduced cardiovascular events at 
3.9 years in people with type 2 diabetes without cardiovascular disease.  
Salim Bastaki et.al14 were studied The diabetes mellitus is a metabolic disorder 
resulting from a defect in insulin secretion, insulin action, or both. Insulin 
deficiency in turn leads to chronic hyperglycemia with disturbances of 
carbohydrate, fat and protein metabolism. As the disease progresses tissue or 
vascular damage ensures leading to serve diabetic complications such as 
retinopathy, neuropathy, nephropathy, cardiovascular complications and 
ulceration. Thus diabetes covers a wide range of heterogeneous diseases. 
Wale kiran K et.al17 were formulated ‘Formulation and development and in-
vitro evaluation of immediate release tablet of sitagliptin phosphate 
monohydrate. This investigation undertaken with an aim to develop 
pharmaceutically equivalent, stable, cost effective and quality improved 
formulation of sitagliptin phosphate monohydrate immediate release tablets. 
Wet granulation method was adopted to prepare the sitagliptin phosphate 
monohydrate immediate release tablets by using micro crystalline cellulose, 
lactose as diluents, crosspovidone and sodium starch glycolate as super 
disintegrant in different concentration (2-8%) to prepare (S1-S9) batches. 
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Tablets were prepared and evaluated for hardness, friability, weight variation, 
content uniformity, and disintegration time and in-vitro drug release. 
Abbaraju prasanna Lakshmi et.al18 was prepared ‘Formulation and 
evaluation of taste masked orally disintegrating tablets of sitagliptin phosphate 
monohydrate’. The unpleasant taste of sitagliptin phosphate monohydrate with 
mannitol by co-grinding method and formulate oral disintegrating tablet by 
direct compression method. Drug-mannitol complxes were taken in 1:1, 1:1.5 
and 1:2 ratio and tested for in vitro and in vivo bitter masking capacity of 
mannitol, drug content and molecular property. Different super disintegrants 
like crosscarmellose sodium, sodium starch glycollate and crosspovidone was 
used as disintegrating agents. The prepared tablets were characterized for tensile 
strength, wetting time, water absorption ratio and in vivo disintegration time. 
Desai P et.al26 were formulated ‘Formulation and evaluation of fast dissolving 
film of Domperidone’. Domperidone is a specific blocker of dopamine receptors 
solvent casting method was used for preparation of fast dissolving film. Various 
film forming polymers were evaluated for selection of suitable polymer. 
Different polymers like maltodextrin, PVA and different grades of HPMC like 
HPMCE5 LV, HPMC E15 LV and HPMC E3 LV were used in the study for 
selection of polymers. Amongst them HPMC E3 LV, HPMC E5 LV was 
selected as film forming polymers and propylene glycol was used as plasticizer. 
For solubility enhancement inclusion complex from β cyclodextrin was prepared 
by kneading method. Films were evaluated for physical and mechanical 
properties, drug content, disintegration time, in vitro dissolution study. Prepared 
films showed satisfactory physical and mechanical properties. Drug-excipients 
interaction study (IR), differential scanning calorimetry (DSC), drug content, 
disintegration time and in vitro dissolution were also acceptable. 32 factorial 
design were used for optimization of film formulation. Batch F4 was fund to be 
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optimized film formulation which has 35.33 sec disintegration time, tensile 
strength 2.180 N/cm2, drug release 75.26% after 15 min. accelerated stability 
studies on the promising formulations indicated that there were no significant 
changes in drug content, in vitro disintegration time, tensile strength, in vitro 
dissolution and surface pH. 
Buchi N.Nalluri et.al27 was prepared ‘Development and evaluation of mouth 
dissolving films of sumatriptan succinate for better therapeutic efficacy’. 
Sumatriptan succinate (SUM) to enhance convenience and compliance to the 
elderly and pediatric patients for better therapeutic efficacy. Film former, 
HPMC along with film modifier/solubilizing agent, PVPK 30 and sodium lauryl 
sulphate (SLS) were used to formulate MDFs. The MDFs were prepared by wet 
film applicator technique and were evaluated for in-vitro dissolution 
characteristics, in vitro disintegration time, and their physic-mechanical 
properties. MDFs with 13% (w/w) of HPMC E15. MDFs with PVP K 30 and 
SLS gave superior dissolution properties when compared to MDFs with SLS. 
Overall, SUM MDFs showed good mechanical properties like tensile strength, 
folding endurance and% elongation and dissolution properties. These results 
suggest that the HPMC is an excellent film former which gives rapid drug 
release. 
P. Narayana raju et.al28 were prepared ‘Formulation and evaluation of fast 
dissolving films of Loraditine by solvent casting method’. Rapidly dissolving 
films of loratidine were developed using low viscosity grades of HPMC as film 
forming polymers. HPMC is a water soluble synthetic polymer which was used 
as film former form many years. The films of loratidine were prepared by 
solvent casting method using Di-chloromethane and methanol as solvents. The 
prepared films were evaluated for drug content, weight variation, thickness and 
in vitro and in vivo disintegration time. Loratidine is moderately bitter drug, 
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taste masking was achieved by use of sweeteners, flavors and citric acid. Type 
of flavor significantly affected the taste masking property. The in-vitro and in 
vivo disintegration time of the optimized formulation was found to be below 29 
seconds and 24 seconds respectively. The prepared films exhibited good 
integrity and thickness. In vitro dissolution studies were performed as per the 
FDA dissolution guidelines for about 10 minutes, the optimum formulation 
released complete drug within 4-6 minutes. DSC and FT-IR studies showed no 
drug polymer integration. 
Komaragiri sasi deepthi et.al29 was investigated ‘Formulation and 
characterization of Atenolol fast dissolving films’. Atenolol is a β selective 
adrenergic antagonist used as antihypertensive agent. Films were prepared using 
film forming polymer like HPMC E5 (F1-F8) and tween 80 is added to the 
formulation from F5-F8 by solvent casting technique with the help of PEG 400 
as plasticizer and glycerine as sweetening agent. FT-IR analysis was performed 
to study the interaction between the drug and polymer. The films were evaluated 
for weight variation, surface pH, folding endurance, drug content, dissolving 
time, disintegration time, and in-vitro dissolution studies. Based on the 
evaluation parameters F4 containing drug: polymer (1:4) ratio showed optimum 
performance and marked increase in releasing of drug 92.34%, though F8 
formulation has maximum drug release as it has less tensile strength. It can be 
concluded in the study that mouth dissolving film can be potential novel drug 
dosage form for poorly water soluble drugs. 
Pavani.S et.al30 prepared ‘Formulation development and evaluation of taste 
masked oral disintegrating films of Atenolol’. Atenolol is β1- selective 
adrenergic blocker and widely used in the treatment of hypertension and angina 
pectoris. It has a bioavailability of 40-50%. The main objective of the study was 
to formulate taste masked oral disintegrating films of Atenolol to achieve a 
Literature Review 
 
 
Cherraan’s College of Pharmacy  28 
 
better dissolution rate by improving the bioavailability of the drug and providing 
quick onset of action there by enhancing patient compliance. Oral disintegrating 
films prepared by solvent casting method using film forming polymer HPMC 
E15 in different ratios. The prepared films were evaluated for the drug content, 
weight variation, film thickness, disintegration time and in-vitro dissolution 
studies and taste mask studies on healthy human volunteers. Among all, the 
formulation F3 containing HPMC E15 (drug : polymer of 1:2) was found to be 
the best formulation which releases 99.89% of the drug within 20 minutes and 
disintegration time is 15.3 sec. 
Raghavendra rao et.al31 were developed ‘Design and development of fast 
dissolving thin films of losartan pottasium’. The fast dissolving films of losartan 
potassium were prepared by solvent casting method using film forming polymer 
HPMC 15 and 50 cps and PEG is used as a plasticizer. The electron microscopy 
showed that the films are clear, colorless with smooth surface and little pores, 
without any scratches on the films. All the films prepared were evaluated for 
physical appearance and surface texture, weight uniformity of films, thickness 
of the films, folding endurance, surface pH, drug content uniformity and in-vitro 
disintegration time of films. All the results were found to be satisfactory. The 
t50% and t90% values decrease with increase in the concentration of SSG, CCS and 
CP. The rapid increase of in dissolution of losartan potassium with the increase 
in CCS. Among all the film formulation FA2 and FA8 (6% CCS, HPMC 15 and 
50 cps) were found to be promising and showed a disintegration time of 36 and 
32 seconds, respectively and 50% of drug released in 9.74 and 8.19 minutes, and 
90 5 of drug release in 18.00 and 17.12 minutes respectively. Based on the 
above results it can be concluded that the fast dissolving oral film of losartan 
potassium may produce the rapid action there by enhance the absorption by 
avoiding the first pass effect.    
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Talele swati G et.al32 was prepared ‘Formulation and evaluation of mouth 
dissolving film of Almotriptan malate’. The present study was aimed to 
formulate and evaluate mouth dissolving films of almotriptan malate using 
polymers HPMC E-15 and HPMC E-4 and gelatin as the film forming agents. 
Formulation batches formulated using 32 full factorial designs. The fast 
dissolving oral films were designed using optimal design and numerical 
optimization technique was applied to find out the best formulation. PEG 400 
was incorporated as plasticizer to improve flexibility of films. Aspartame as 
sweetener. Sodium starch glycolate used as disintegrant. An attempt was made 
to prepare mouth dissolving films of almotriptan with the purpose of developing 
a dosage form for quick onset of action. The films were prepared by solvent 
casting method. The formulated mouth dissolving films were evaluated for 
physical characteristics such as uniformity of weight, thickness, folding 
endurance, drug content, surface pH, percentage elongation and tensile strength 
and gave satisfactory results. The formulation were subjected to disintegration, 
in-vitro drug release. The FTIR studies revealed that no physicochemical 
interaction between excipients and drug. Melt in mouth films of almotriptan 
containing single polymer HPMC E-15 showed best results, in terms of tensile 
strength (1.76±0.11), percentage elongation (36.63±0.288%), folding endurance 
(>300), in-vitro disintegration time (26.01±0.11 sec), surface pH (6.20±0.001), 
thickness (0.096±0.011 mm) and percentage content uniformity (97.23±0.091). 
satisfactory dissolution profile was obtained with maximum release of 96% of 
drug within 120 sec. The stability studies showed that there was no appreciable 
change in parameters when stored at three different temperatures. 
Kranthi kumar.v et.al33 developed ‘Formulation and evaluation of carvedilol 
fast dissolving sublingual films’. Carvedilol, a nonselective β blocker is an 
antihypertensive drug which has oral bioavailability of 25-35% with 
conventional dosage forms due to first pass metabolism. The present study 
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investigated the possibility of developing carvedilol fast dissolving sublingual 
films allowing fast, reproducible drug dissolution in the oral cavity, thus 
bypassing first pass metabolism to provide rapid onset of action of the drug. The 
fast dissolving films were prepared by solvent casting method. Low viscosity 
grade of HPMC E3 and HPMC E5 were used as film forming polymers. In this 
study tween 80 was used as solubilizing agent as well as plasticizer. All the film 
formulations F1-F9 were evaluated for their thickness, weight variation, tensile 
strength, percentage elongation, folding endurance, in-vitro disintegration, drug 
content, in-vitro drug release and ex-vivo permeation studies. Disintegration 
time showed by the formulations was found to be in range of 25-50 sec. 
Formulations F7 was chosen as the best formulation which showed 96.65 % in-
vitro drug release within 5 minutes and 62.36% ex-vivo drug permeation within 
60 mins. The film showed an excellent stability at least for 45 days when stored 
at 40°c and 75% relative humidity. 
Deepthi et.al34 was prepared ‘Formulation and evaluation of fast dissolving oral 
films of Zolmitriptan’. The present study was aimed to formulate and evaluate 
fast dissolving oral films of Zolmitriptan using sodium alginate, xanthan gum 
and sodium starch glycolate, guar gum. The suitable plasticizer and its 
concentration were selected on the basic of flexibility, tensile strength and 
stickiness of the film. The films are prepared by solvent casting method and 
characterized by UV, FTIR studies. The films were evaluated for disintegration 
time, Folding endurance, Tensile strength, Mouth dissolving time, Thickness, 
content uniformity and in-vitro dissolution studies. The F5 formulation has 
given 98.5% drug release within 6 minutes and has a tensile strength of 1.80 
MPa. 
Ali MS et.al35 was formulated ‘Formulation and evaluation of fast dissolving 
oral films of Diazepam’. Oral films rapidly along with drug in mouth and 
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majority of the drug is absorbed through buccal/oral mucosa into systemic 
circulation avoiding first pass metabolism. Diazepam is an antiepileptic drug 
which is normally administered by intramuscular route or as rectal suppository 
in acute conditions of seizure emergencies. Oral films were prepared by solvent 
casting method using HPMC E3, E5, and HPMC E15 as a film formers and 
propylene glycol, PEG 400 as plasticizers and evaluated for mechanical 
properties, disintegration and in-vitro drug release. The optimized (F4A) 
formulation (HPMC E5 and PEG 400) exhibited drug release of 99.89 %in 15 
minutes which was significantly high when compared to marketed tablet valium 
(68.81 %). 
Alka tomar et.al36 was formulated ‘Formulation and evaluation of fast 
dissolving oral film of Dicyclomine as potential route of buccal delivery’. The 
aim of the study is to formulate and evaluate the (FDOF) of an anticholinergic 
drug (Dicyclomine) and improved bioavailability of drugs as compared to 
conventional solid oral dosage forms. Oral films were prepared by using HPMC, 
PVA, Eudragid RL-100, combination of two polymers and other excipients. 
Films were prepared by solvent casting method. Films were evaluated for 
mechanical properties, morphology study, swelling properties, disintegration 
time, dissolution time, and in-vitro drug release. X1 formulation shows 
maximum in-vitro drug release 93.88%, following first order kinetics (r2 
=0.9915). The release exponent ‘n’ was found to be for X1 is 0.4487, which 
appears to indicate that the drug release was controlled by first order release. 
Anjum pathan et.al37 developed ‘Formulation and evaluation of fast dissolving 
film oral film of Promethazine hydrochloride using different surfactant’. The 
aim of the present study is to formulate and evaluate the fast dissolving oral film 
of promethazine hydrochloride. Promethazine hydrochloride as a strong 
antihistamine which are used to reduce nausea, motion sickness and improved 
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bioavailability of drugs as compared to conventional solid oral dosage forms. 
The films were prepared HPMC E15 as a film base synthetic polymer and PEG 
400 as a plasticizer by solvent casting method. SLS and MCC used as surfactant 
in different concentration. Sucrose used as sweetening agent and strawberry as a 
flavoring agent. Films were found to be satisfactory when evaluated for 
thickness, weight variation, in-vitro drug release, folding endurance, drug 
content and disintegration time. The surface pH of the all films was found to be 
neutral or minor charge. Films in-vitro drug release studies also done by using 
dissolution apparatus. The in-vitro drug release in optimized formulation F2 was 
found to be 14.36% in 2 min. the optimized formulation F2 also showed 
satisfactory pH, drug content (97.41±0.54), effective in vitro drug release 
(96.03±0.68% in 16 min), disintegration time of 9 seconds and satisfactory 
stability. The promethazine hydrochloride fast dissolving oral film was 
formulated. The given film disintegrates within 9 seconds which release drug 
rapidly and gives action. 
Kamalesh upreti et.al38 designed ‘Formulation and evaluation of mouth 
dissolving films of Paracetamol’. In the resent study, mouth dissolving films of 
paracetamol were prepared by solvent casting method. Several formulations 
were developed by varying polymer (HPMC) and plasticizer (glycerol) 
concentrations. Sweetening and flavoring agents were also added to make the 
formulation palatable. The films were evaluated for thickness, folding 
endurance, weight variation, disintegration time, dissolution time and drug 
content. In the present study, each mouth dissolving film was 2×3 cm in size and 
contained 125 mg paracetamol (PCM). Thickness of the films were 
approximately 2mm. the strip disintegrated completely within 4 mins. In-vitro 
dissolution studies were carried out in distilled water as well as in simulated 
salivary fluid (pH 6.8). The optimized formulations showed 92% drug release 
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within 30 min. The prepared stripes seem to be an attractive alternative to 
conventional marketed formulations. 
Mital.s.panchal et.al39 formulated ‘Formulation and evaluation of mouth 
dissolving film of Ropinirole hydrochloride by using pullulan polymers’. The 
films of ropinirole hydrochloride were prepared by using polymers such as 
pulllan and PEG 400 as plasticizer, by a solvent casting method. Formulation 
batches were formulated with the help of 32 full factorial designs. The fast 
dissolving oral films were prepared using optimal design and numerical 
optimization technique was applied to find out the best formulation. The 
formulated mouth dissolving films were evaluated for physical characteristics 
such as uniformity of weight, thickness, folding endurance, drug content, 
surface pH, percentage elongation and tensile strength and gave satisfactory 
results. The formulation were subjected to disintegration, in-vitro drug release 
tests and stability study. The FTIR and DSC studies revealed that no 
physicochemical interaction between excipients and drug. A marked increase in 
the % drug release was exhibited by mouth dissolving films of Ropinirole 
hydrochloride containing pullulan as a polymers at 60 sec., when compared to 
other polymer films. Mouth dissolving film of Ropinirole hydrochloride 
containing as pullulan showed 99.48±0.18% drug release at 60 sec. mouth 
dissolving films of Ropinirole hydrochloride containing pullulan showed better 
tensile strength (9.67±0.064g/mm2), percentage elongation (21.59±0.29 %), 
folding endurance (88.00 1.00 no. of folds), in-vitro disintegration time 
(20.33±0.57 sec), surface pH (6.60±0.10 pH), thickness (0.07±0.01 mm) and 
percentage content uniformity (99.53±0.37 %). Stability studies revealed that 
optimized formulation was stable. Mouth dissolving films of Ropinirole 
hydrochloride can be considered suitable for clinical use in the treatment of 
parkinson’s disease and rest leg syndrome, where a quicker onset of action for a 
dosage form is desirable along with the convenience of administration. 
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Thonte S.S et.al40 were formulated ‘Formulation and Evaluation of Oral 
Dissolving film of glibenclamide’. The aim of the present study was to 
formulate fast dissolving films of Glibenclamide using HPMC K-15, HPMC E-
15 HPMC K-100 PEG (400) as a plasticizer, tween 80 as a surfactant, and citric 
acid as a salivary agent. Glibenclamide solid dispersion of PEG 6000 is 
dispersed in the polymer solution. Films were prepared by the solvent casting 
method and found to sati\sfy the mouth dissolving time and other film 
parameters. The film instantly gets wet by saliva, rapidly hydrates, adheres to a 
tongue and rapidly disintegrates and dissolves to release the drug for the oro-
mucosal absorption or allow for gastrointestinal absorption to be achieved when 
swallowed. The formulated films exhibited acceptable films endurance. The 
time required films exhibited acceptable films endurance. The time required for 
the film to dissolve and release 26 seconds and 2 minutes respectively. It can be 
concluded from the study that the oro-flash   release film can be a potential 
novel drug dosage form for poorly water-soluble drugs. 
DR. D.Nagendrakumar et.al41 were designed ‘Formulation and evaluation of 
fast dissolving oral films of Metoprolol succinate’. The key is to develop 
successful oral film by solvent casting method and selected the right compatible 
excipients using FTIR studies. Oral films were fabricated using HPMC E5 and 
HEC polymer. The prepared films were evaluated for organoleptic evaluations, 
film weight, thickness, folding endurance, tensile strength, drug content 
uniformity, surface pH, disintegration time and in-vitro dissolution studies. The 
formulation F5 has disintegration time of 7 seconds and is more promising and 
showed drug release of 98% after 5 minutes; hence formulation F5 was selected 
as best formulation. 
 Poonam A.padamwar et.al42 was prepared ‘Formulation and evaluation of fast 
dissolving oral films of Bisoprolol fumarate’. The films were prepared by using 
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polymers such as HPMC and maltodextrin, plasticizer such as PEG 400, by a 
solvent casting method. The formulated fast dissolving films were evaluated for 
physical characteristics such as uniformity of weight, thickness, folding 
endurance, drug content, surface pH, percentage elongation and tensile strength 
and gave satisfactory results. The formulation were subjected to disintegration, 
in-vitro drug release. The in-vitro disintegration time of the optimized batch F4 
was found to be 20 sec. The optimized batch was found be stable for 1 month 
under specified stability conditions. 
Sarita rana et.al43 was developed ‘Formulation and evaluation of Domperidone 
fast dissolving film by using different polymers’. Developing a fast dissolving 
delivery system releasing domperidone concomitantly in stomach for treating 
vomiting and motion sickness. Domperidone FDFS was prepared by solvent 
casting principle. Different concentration of film forming polymer i.e. 
domperidone with and without solubilizing agent tween 80 had better. 
Korsmeyer-peppas model was found to be fit kinetic in which all formulation 
showed good linearity (R2: 0.906 to 0.989), with slope (n) values ranging from 
0.655 to 0.981. In korsmeyer-peppas model, ’n’ is the release exponent 
indicative of mechanism of drug release. The ‘n’ values ranged from 0.5-1.0 
indicate anomalous transport (non-fickian) diffusion where drug release is both 
diffusion and swelling controlled. 
Julie Mariam Joshua et.al44 were designed ‘Formulation of propranolol 
hydrochloride oral thin films for migraine prophylaxis’. Propranolol Hcl is a non 
–selective β adrenergic antagonist completely absorbed from the GIT tract. The 
purpose of developing these dosage form is to reduce the dose by bypassing its 
first pass metabolism. Films were prepared from F1-F6 by solvent casting 
technique. Pullulan was selected as polymer because of its good water solubility 
and propylene glycol as plasticizer. PVP was selected as disintegrant, citric acid 
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as saliva stimulating agent, mannitol as sweetening agent and menthol was used 
as flavoring agent. The compatibility of the drug in the formulation was 
confirmed by FTIR and DSC. Formulated films were subjected to various 
evaluation parameters. Based on the evaluation parameters, F4 has 
disintegration time of 47 sec and showed promising drug release of 93% after 20 
min. SEM of F4 showed smooth surface and little pores. The stability study 
proved that the formulation F4 was found to be stable in both refrigerator and 
room temperature. Ex-vivo permeation study of F4 showed 91% of drug 
permeation through goat oral mucosa: hence formulation F4 was selected as best 
formulation. 
Farhana sultana et.al45 designed ‘Preparation and evaluation of fast dissolving 
oral thin films of Caffeine’. Films were prepared by using HPMC 15 cps, 
sodium alginate& kollicoat IR white in various proportions. Total nine 
formulations were prepared and conducted various physicochemical evaluations 
including FT-IR and in-vitro dissolution studies from the trinocular microscopic 
images. It appears that kollicoat IR white is more porous which may be due to 
the characteristic behavior of graft of co polymer was reflected in its lowest 
disintegration time (12 sec) and its cumulative percentage release was 99.86% 
within 240 seconds. Films in formulation F1 prepared with HPMC were very 
flexible, smooth and its in-vitro disintegration time was 13 seconds. Its 
cumulative percentage drug release was 100% within 120 seconds which is 
remarkable in comparison to other formulations.  
Thonte S.S et.al46 was prepared ‘Formulation and evaluation of oral fast 
dissolving film of Glipizide’. Films were formulated using HPMC K-15, HPMC 
E-15, HPMC K-100 and PEG 400 was used as plasticizer to give flexibility to 
the films. In FT-IR study inter was drug and excipients. Three blank films were 
selected for the in comparison of drug. After characterization the drug loaded 
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films and studied their dissolution time and in-vitro drug release studies, among 
all the formulations (F1-F10) F3,F4,F5,F6,F7&F9 has selected the best 
formulation as its disintegration and dissolution time was less and it releases the 
drug to a greater extent from 93% to more than 100% in 10 minutes. From F9 
was selected best formulation as its disintegration and dissolution time was less. 
And released drug to a greater extent compared to other formulation. Therefore 
fast dissolving oral films can play an important role in oral drug delivery. Drug 
loaded films with both the polymers were stable under 40°C/75%RH conditions.  
Pravin kumar sharma et.al47 developed et.al ‘Development and evaluation of 
fast dissolving oral film of poorly water soluble drug Felodipine’. Solid 
dispersions of was prepared using solvent evaporation method using PVP K30 
as hydrophilic polymeric carrier in different proportions. Felodipine FDFs were 
prepared using solvent casting method. The concentration of HPMC E5 as film 
forming polymer, propylene glycol as plasticizer and crosscarmellose as 
disintegrating agent and selected as response variables. Evaluated weight 
variation, thickness, drug content, folding endurance, surface pH, moisture 
content, percentage swelling, percentage elongation, tensile strength, in-vitro 
disintegration, in-vitro dissolution, stability study, surface morphology using 
SEM, ex-vivo permeation study and in-vivo pharmacokinetic study. FTIR and 
DSC analysis revealed that the compatibility between the drug and excipients. 
Felodipine FDFs indicated disintegration time of 22.84±0.33 and in-vitro 
percentage drug dissolution. 
Rubia Yasmeen et.al55 formulated ‘Preparation and evaluation of oral fast 
dissolving films of citalopram hydro bromide’. Citalopram is an antidepressant 
also used for mood disorders such as anxiety and obsessive and compulsive 
disorder. Fast dissolving films of citalopram hydro bromide were prepared by 
solvent casting technique. HPMC E5 was selected as polymer because of its 
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good water solubility. Propylene glycol as plasticizer and sorbitol as sweetener 
were used in the formulation. The compatibility of the drug in the formulation 
was confirmed by FTIR studies. Surfactants by their wetting ability further 
reduce disintegration time and enhance the drug release in mouth dissolving 
films, so tween 80 at concentrations of 10% w/w of polymer concentration was 
included some formulations. By varying the concentration of polymer and 
surfactant, four formulations F1, F2, F3 and F4 were formulated. The prepared 
films were evaluated for there by physic -chemical parameters like folding 
endurance, weight variations, thickness, surface pH, dissolving time and 
disintegration time. Estimation of drug content of films was performed and the 
results were satisfactory. In vitro dissolution studies revealed higher drug 
release from formulations F3 and F4. The order of drug release was found to be 
F3>F4>F1>F2.  
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5 DRUG PROFILE 
SITAGLIPTIN PHOSPHATE15, 16 
STRUCTURE 
 
Fig 5: structure of Sitagliptin phosphate 
IUPAC NAME 
 (R) -4-oxo-4-[3-(tri fluro methyl)-5,6-dihydro[1,2,4] trizolo [4,3-a] pyrazin-
7(8H)-yl-]-1-(2,4,5-triflurophenyl) butane-2-amine. 
CHEMICAL DATA17 
Formula  : C16H15F6N5O 
Molecular mass : 407.314 g/mol 
Molecular weight : 532.32 
Melting point  : 205-206° 
Physical state  : It a white to off-white, crystalline non-hygroscopic 
powder. 
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MECHANISM OF ACTION18 
Sitagliptin works to competitively inhibit the enzyme Dipeptidyl peptidase 4 
(DPP-4). This enzyme breaks down the incretin GLP-1 and GIP, gastrointestinal 
hormones released in response to a meal. By preventing GLP-1 and GIP 
inactivation, there are able to increase the secretion of insulin and suppress the 
release of glucogan by the alpha cells of the pancreas. This drives blood glucose 
levels towards normal. As the blood glucose level approaches normal, amount of 
insulin released and glucogan suppressed diminishes, thus tending to prevent an 
overshoot and subsequent low blood sugar (hypoglycemia). 
PHARMACOKINETICS19 
Absorption 
Sitagliptin is rapidly absorbed, with a 100 mg dose reaching a Cmax of 950 nm in 
1-4 hr ; AVC was 8.52 MC M. The bioavailability is approximately 87%. 
Distribution 
Vd is approximately 198L. Plasma protein binding is 38%. 
Metabolism 
Metabolism by CYP 3A4 and, to a lesser degree, CYP 2C8. 
Elimination 
Terminal half -life is approximately 12.4 hr and renal clearance is approximately 
350 mL/min. Approximately 13 is excreted in the feces and 87% in the urine via 
active tubular secretion (79% as unchanged drug). Sitagliptin is a substrate for 
organic anion transport. 
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DRUG INTERACTION 
Cyclosporin: 
Sitagliptin phosphate plasma concentrations may be increased modestly 
(approximately 68 %) which is not expected to be clinically important. 
Digoxin: 
Digoxin plasma concentrations may be increased slightly (approximately 18%); 
no dosage adjustment is recommended. 
Insulin, Sulphonylureas (e.g tolbutamide) 
A lower dose of insulin or sulphonyl urea may be needed to reduce the risk of 
hypoglycemia. 
DOSAGE AND ADMINISTRATION20 
Adults 
PO 100 mg once daily. 
Renal function impairment 
Adults moderate renal impairment (Cr Cl 30 to less than 50 ml/min or 
approximately serum creatinine levels of more than 1.7 upto 3 mg/dl in men and 
more than 1.7 upto 2.3 mg/dl in women). 
PO 50 mg once daily 
Severe renal impairment (Cr Cl less than 30 ml/min or approximate serum 
creatinine levels of more than 3 mg/dl in men and more than 2.5 mg/dl in women). 
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PO 25 mg once daily 
ESRD requiring hemodialysis or potential dialysis. 
PO 25 mg once daily 
Administer without regard to the timing of hemodialysis. 
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 6. EXCIPIENTS PROFILE 
6.1 HPMC21 
Structural formula: 
 
 
Fig 6: structure of HPMC 
 
Chemical name : Cellulose hydroxyl propyl methyl ether. 
Chemical data 
Molecular mass : OCH2CH (OH) CH3 
Molecular weight: 10,000-1500000 
Melting point : 190-200°C 
Physical state : HPMC is an odorless & tasteless or creamy white fibrous or    
   granular powder.  
Solubility: 
Soluble in cold water, forming a viscous colloidal in soluble in hot water, 
chloroform, ethanol, dichloromethane, mixtures of water &alcohol. 
Incompatibilities: 
Incompatible with some oxidizing agents, organic ions to form insoluble 
Excipients Profile  
 
 
Cherraan’s College of Pharmacy  44 
 
precipitates. 
Stability and storage conditions: 
It is a stable, although it is hygroscopic after drying. 
Stored in well closed container, in a cool & dry place. 
Functional category 
Bio adhesive material, coating agent, controlled release agent, film former, 
emulsifier, solubilizing & stabilizing agent, tablet binder, thickening agent. 
Application of pharmaceutical formulation/ Technology 
❖ It is widely used in oral, ophthalmic, nasal &topical pharmaceutical 
formulations. 
❖ Tablet binder in film coating and as a matrix in extended release tablet 
formulations. 
❖ In liquid orals which is used as a suspending or thickening agent. 
❖ Lower viscosity grades are used in aqueous film coated solution, while 
higher viscosity grades are used with organic solvent. 
❖ It is also used in cosmetic and food products. 
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6.2 PROPYLENE GLYCOL21 
Structural formula: 
 
Fig 7: structure of propylene glycol 
IUPAC NAME: 1, 2- dihydroxy propane, E1520; 2- hydroxyl propanol. 
Chemical name 
 1, 2-propane diol 
  (-)-1, 2 propane diol 
 (+)- 1, 2 propane diol 
Description 
Propylene glycol is a clear, colorless, viscous, practically odorless liquid with a 
sweet, slightly acrid taste resembling that of glycerin. 
Typical properties 
Boiling temperature : 188 c 
Density : 1.038 g/cms at 20 c 
Flammability : upper limit, 12.6%v/v in air; lower limit, 2.6% v/v in air. 
Melting point : 59°C 
Solubility : with acetone, chloroform, ethanol (95 %), water. 
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Incompatibilities  
Propylene glycol is incompatible with oxidizing reagents such as potassium 
permanganate. 
Stability and storage conditions 
At cool temperatures, propylene glycol is stable in a well closed container, but at a 
high temperatures, in the open, it tends to oxidize, giving rise to products such as 
propionaldehyde, lactic acid, pyruvic acid, and acetic acid. Propylene glycol is 
chemically stable when mixed with ethanol (95%), glycerin or water; aqueous 
solutions may be sterilized by autoclaving. 
Functional category: 
Antimicrobial preservative, disinfectant, humectant, plasticizer, solvent, 
stabilizing agent, water –miscible co solvent. 
Application in pharmaceutical formulation or technology 
Propylene glycol has become widely used as a solvent, extractant, and 
preservative in a variety of parendral and nonparendral pharmaceutical 
formulation. It is a better general solvent glycerine and dissolves a wide variety of 
materials, such as corticosteroids, phenols, sulfa drugs, barbiturates, vitamins (A 
and B), most alkaloids, and many local anesthetics. It is commonly used as a 
plasticizer in aqueous film-coating formulations. 
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6.3 POLYETHYLENE GLYCOL21 
Structural formula:  
 
Fig 8: Structure of PEG 
IUPAC name :  α- hydro- -hydroxy poly (oxy-1, 2, ethane diyl) 
Description :  PEG occurs as clear, colourless or slightly yellow coloured,  
  viscous liquids. 
Typical properties  
Density  : 1.120 g/cm3 
Melting point  : 37-40 C° 
Solubility :  
All types of PEG soluble in water and miscible in all proportions with other PEG. 
PEGs are soluble in acetone, alcohol, benzene, glycerine, & glycol. 
Incompatibilities : 
It may be incompatible with some colouring agents. It reduces the antibacterial 
activity of penicilins. The preservative effect of parabens may also be impaired to 
binding with PEG. 
Stability and storage conditions 
Excipients Profile  
 
 
Cherraan’s College of Pharmacy  48 
 
PEG are chemically stable in air and in solution although grades with a molecular 
weight less than 2000 are hygroscopic. 
Functional category: 
Ointment base, Plasticizer, Solvent, Suppository base, Tablet & Capsule lubricant. 
Application in pharmaceutical formulation or technology 
Poly ethylene glycol is used in pharmaceutical formulations including Parendral, 
topical, ophthalmic, oral & rectal preparation. It has used biodegradable polymeric 
matrices used in controlled release systems. 
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6.4 CITRIC ACID21 
Structural formula  
 
Fig 9: Structure of citric acid 
 
Chemical name :  2- hydroxy-1, 2, 3- propane tricarboxylic acid 
Chemical data 
Molecular formula :  C6H8O7.H2O 
Molecular mass       :  210.14 
Melting point           : 100°C 
Physical state : Colorless, white crystalline, efflorescent powder. 
Odorless & has a strong acidic taste. 
Solubility : 
Soluble in ethanol (95%), water, sparingly soluble in ether. 
Stability and storage condition: 
Citric acid loses water of crystallization in dry air or when heated about 40°C. It is 
slightly deliquesant in moist air.  
Citric acid anhydrous material should be stored in airtight containers in a cool & 
dry place.   
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Functional category: 
Acidifying agent, antioxidant, buffering agent, chelating agent, flavor enhancer, 
preservative. 
Applications in pharmaceutical formulation /Technology 
❖ Citric acid is used in pharmaceutical formulations and food products. It 
also has been used to adjust the pH of the tablet matrices in enteric coated 
formulation for colon-specific drug delivery. 
❖ It is used in the preparation of effervescent granules, while anhydrous 
citric acid is used in the preparation of effervescent tablets. 
❖ Improve the stability of spray dried insulin powder in inhalation 
formulation. 
❖ In food products, used as flavor enhancer for its acidic taste. 
❖ Sequestering agent. 
❖ Antioxidant synergist. 
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6.5 SACCHARIN SODIUM21 
Structural formula 
 
 
Fig 10: Structure of sodium saccharin 
 
Chemical name :  1, 2 –benzisothiazol-3 (2H) –one 1, 1-dioxide, sodium  
  salt. 
Description  : White, odorless, efflorescent crystalline powder. 
Chemical data: 
Formula :  C7H4NNaO3S 
Molecular mass :  205.16 
Density : 0.8-1.1 g/cm3 
Melting point :  Decomposes when heating. 
Physical state : White, odorless, efflorescent crystalline powder. 
Solubility:  
Soluble in buffer solution, ethanol, ethanol (95%), propylene glycol, propan-2 -ol 
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& water. 
Incompatibilities: 
Saccharin sodium does not undergo Millard browning. 
Stability and storage conditions 
Stable under normal range of conditions employed in formulation only. When it is 
exposed to a high temperature (125°C) at low pH for over 1 hour significant 
decomposition occur. 
Functional category 
❖ Sweetening agent 
❖ Application of pharmaceutical formulation/Technology 
❖ It is used as sweetening agent in beverages, food products, table top 
sweeteners and pharmaceutical formulation such as tablets, powders, 
medicated confectionary, gels, suspension, liquids and mouthwashes. 
❖ Also used in vitamin preparations. 
❖ Injection of sodium saccharin has been used to measure the arm-tongue 
circulation time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methodology 
Methodology  
 
 
Cherraan’s College of Pharmacy  53 
 
7. METHODOLOGY 
 
7.1 MATERIALS AND METHODS 
 
Table 6: List of materials 
Material Manufacturer 
Sitagliptin phosphate Dr. Reddy’s laboratory 
HPMC E15 Accent microcell industries 
HPMC E50 Symonds pvt ltd 
PEG 400 BASF 
Propylene glycol Spectrum chemicals 
Sodium saccharin Aptuit laurus ltd 
 
Table 7: List of Equipments 
Name of Instrument Model and Manufacturer 
Digital balance Mettler Toledo PR203 
Hot air oven Thermolab 
UV Spectrometer Lab india UV 3000 
Dissolution test Apparatus Lab india D5 8000 
Micrometer screw gauge Mitutoyo,  china 
Disintegration test apparatus USP Electro Lab 
pH meter Electro Lab 
Stability chamber Thermo lab Pvt ltd 
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7.2 PREFORMULATION STUDIES22-25 
Preformulation may be described as the stage of development during which the 
physicochemical and biopharmaceutical properties of a drug substance are 
characterized. It is an important part of the drug development process. The 
information relating to drug development acquired during this phase is used for 
making critical decisions in subsequesant stages of development. A wide variety 
of information must be generated to develop formulations rationally. 
Characterization of the drug is a very important step at the preformulation phase 
of product development followed by studying the properties of the excipients on 
their compatibility. 
7.2.1 Solubility26, 27 
Solubility is expressed in terms of parts per million of solvent in which 1g of solid 
is soluble. Solubility of the powder in different solvents like water, ethanol etc 
was determined at 20°c. 
7.2.2 Heavy metal content28, 29 
The part of Lead per million parts of powder was examined by comparing sample 
solution with 10 ppm lead standard solution for 2 gm material. 
7.2.3 Melting point30 
The melting point was carried out by using capillary tube method. 
7.2.4 Compatibility Studies31-33 
FTIR study was carried out to check the compatibility of drug with polymers. 
Infrared spectrum of sitagliptin phosphate was determined on Fourier transform 
Infrared spectrophotometer using KBr dispersion method. The baseline correlation 
was done using dried potassium bromide. Then the spectrum of dried mixture of 
drug and Pottasium bromide was run followed by drug with various polymers by 
using FTIR spectrophotometer. The absorption maximums in spectrum obtained 
with the substance being examined correspond in position and relative intensity to 
those in the reference spectrum. 
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7.3 FORMULATION DEVELOPMENT OF SITAGLIPTIN  
PHOSPHATE ORAL FILM34-36 
Table 8: Formulation trials 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Sitagliptin 
phosphate (g) 
0.625 0.625 0.625 0.625 0.625 0.625 0.625 0.625 0.625 
HPMC E15 
(g) 
1.0 1.25 1.5 - - - 1.25 - 1.25 
HPMC E50 
(g) 
- - - 1.0 1.25 1.5 - 1.25 1.25 
PEG 400 (g) 1.5 1.25 1.0 - - - - 1.25 - 
Propylene 
glycol (ml) 
- - - 1.5 1.25 1.0 1.25 - - 
Citric acid (g) 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 
Sodium 
saccharin (g) 
0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
Flavor (g) 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
Distilled water 
(ml) 
Qs Qs Qs Qs Qs Qs Qs Qs Qs 
 
 
 
 
 
 
 
 
 
 
 
Fig 11 : Fast Dissolving Film 
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7.3.1 PROCEDURE37-40  
The water soluble polymers and plasticizers were dissolved in distilled water. The 
solution is stirred up for 2 hrs in the magnetic stirrer and kept aside to remove all 
air bubbles entrapped. Meanwhile, the excipients and drug were dissolved and 
stirred well for 30 min, after the completion of stirring both the solutions are 
mixed together. Finally the solution is casted on a suitable petriplate to form a 
film. The plates were kept in a hot air oven at 60° c for 1 hour. The dried film was 
gently separated from glass plate and cut into a desired sizes. 
7.3.2 Dose calculations 
Length of glass plate =10 cm.  
Width of glass plate =10 cm. 
Area of the plate =100 cm2. 
No. of 4 cm2 films present whole plate =100/4 =25 films. 
Each films contains 25 mg of drug. 
25 films contain 625 mg drug (25×25). 
Labelled claim= 25 mg 
7.3.3 Standard Graph of Sitagliptin Phosphate41-43 
 Stock solution was prepared by 50 mg of sitagliptin phosphate in 100 ml 
of water. From this stock solution 10 ml was withdrawn and diluted upto 100 ml 
using water. Calibration curve was prepared by using different concentration (20 
µg/ml-100 µg/ml) by appropriate dilution of stock solution. The absorbance was 
measured at 267 nm.  
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7.4 EVALUATION OF ORAL FILM44 
7.4.1 Thickness45 
A micrometer screw gauge was used to measure the film thickness. In order to 
obtain uniformity of film, thickness is measured at 5 different locations. The 
thickness of the film should be less than 5 %. 
7.4.2 Weight variation46 
Ten films were randomly selected and their average weight was weighed. 
Individual films were weighed and compared with the average weight for the 
deviation. 
7.4.3 Folding endurance47 
To determine folding endurance, a film is cut and rapidly folded at the same place 
till it broke. The number of times the film could be folded at the same place 
without breaking gives the value of folding endurance. Topical folding endurance 
for film was between100-150. 
7.4.4 Percentage elongation48  
It was calculated by 
Percentage elongation = Increase in length of strip × 100 
    Initial length of strip 
7.4.5 Tensile strength49 
Tensile strength is the maximum stress applied to a point at which the strip 
specimen breaks. It is calculated by the formula 
Tensile strength =  Load at failure × 100___ 
   Strip thickness × strip width 
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7.4.6 In-vitro disintegration50, 51 
Disintegrating time is defined as the time (sec) at which a film breaks when 
brought in contact with water or saliva. 
Petri dish method 
2 ml of distilled water was placed in the petri dish and one film was added on the 
surface of water and the time measured until the oral film was dissolved 
completely. 
7.4.7 In-vitro dissolution52 
900 ml of o.1 N HCL was used as a media, at was maintained at 37 +0.5 °c while 
the basket was set at 100 rpm. A film sample of 4 cm2 (2×2 cm) was cut and taken 
into the basket. 5 ml of the sample were taken every 2 minutes and the same 
amount was replaced with fresh 0.1 N HCL. The withdrawn samples were filtered 
and analysed using a UV spectrometer at a wavelength of 267 nm. 
7.4.8 Drug content53 
This test was performed by dissolving a 4 cm2 area of film in 50 ml of 0.1 N HCL 
with stirring. This solution was filtered using a whatmann filter paper, and the 
filtrate was diluted to 100 ml with the same buffer in a volumetric flask. This 
solution was analysed using UV spectrometer.   
7.4.9Assay 
This test was performed by dissolving a 4 cm area of thin film in 50 ml of pH 6.8 
phosphate buffer with stirring. This solution was filtered using a Whatmann filter 
 paper, and the filtrate was diluted to 100 ml with the same buffer in a volumetric 
flask. This solution was analyzed using UV spectrophotometer. 
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7.4.10 Stability studies54 
The stability studies were carried out according to ICH to assess the drug 
formulation stability. Optimized F3 formulation was sealed in Aluminium packing 
laminated with polyethylene. Samples were kept at 40 c and 75% RH for 3 
months. At the end of study period, the formulation was observed for change in 
physical appearance, color, drug content and drug release characteristics. 
7.4.10 SEM analysis56 
The morphological study of oral strip was done by the scanning electron 
microscopy (SEM) at a definite magnification. Study refers the difference 
between upper and lower side of the films. It also helps in determination of the 
distribution of API. 
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8 RESULTS AND DISCUSSION 
8.1 PREFORMULATION STUDIES 
8.1.1 Solubility 
Solubility is expressed in terms of parts per million of solvent in which 1g of solid 
is soluble. Solubility of the powder in different solvents like water, ethanol etc 
was determined at 20°c. 
8.2.2 Heavy metal content 
The part of Lead per million parts of powder was examined by comparing sample 
solution with 10 ppm lead standard solution for 2 gm material. 
8.2.3 Melting point 
The melting point was carried out by using capillary tube method. 
 
Table no 9: API characterization - Sitagliptin phosphate 
S.No Test Specification Result 
1 Description White powder White powder 
2 Solubility Soluble in water Complies 
3 Taste Bitter Complies 
4 Odor Odorless Complies 
5 Heavy metals (ppm) 
Should not be more than 
20 ppm 
Less 
6 Melting point Range :205-207° c 206 °c 
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8.2 CALIBRATION CURVE OF SITAGLIPTIN PHOSPHATE 
Stock solution was prepared by 50 mg of Sitagliptin phosphate in 100 ml of water. 
From this stock solution 10 ml was withdrawn and diluted upto 100 ml using 
water. Calibration curve was prepared by using different concentration (20 µg/ml-
100 µg/ml) by appropriate dilution of stock solution. The absorbance was 
measured at 267 nm. The absorbance of various concentration measured at 267 
nm is as follows in table 10. Standard curve of Sitagliptin phosphate is shown in 
figure 11.  
Table no 10: Standard graph of Sitagliptin phosphate 
 
S. No Concentration µg/ml Absorbance (267 nm) 
1 20 0.228 
2 40 0.436 
3 60 0.641 
4 80 0.864 
5 100 0.998 
 
 
 
 
 
 
 
 
 
 
 
Fig 12: Standard graph of sitagliptin phosphate
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8.3 FT-IR Studies 
FTIR study was carried out to check the compatibility of drug with polymers. 
Infrared spectrum of sitagliptin phosphate was determined on Fourier transform 
Infrared spectrophotometer using KBr dispersion method. The baseline correlation 
was done using dried potassium bromide. Then the spectrum of dried mixture of 
drug and Pottasium bromide was run followed by drug with various polymers by 
using FTIR spectrophotometer. The absorption maximums in spectrum obtained 
with the substance being examined correspond in position and relative intensity to 
those in the reference spectrum. 
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Fig 13:  IR Spectra of Sitagliptin phosphate 
 
 
No. Peak Intensity 
Corr. 
Intensity 
Base (H) Base (L) Area Corr. Area 
1 599.86 61.564 5.035 644.22 561.29 15.901 1.269 
2 1151.5 33.276 9.285 1190.08 1109.07 33.648 3.623 
3 1375.25 46.849 4.9 1394.53 1357.89 11.258 0.773 
4 1519.91 38.144 12.121 1543.05 1490.97 18.539 2.975 
5 1633.71 25.357 7.832 1653 1575.84 36.913 3.504 
6 3450.65 2.846 0.383 3473.8 3433.29 61.349 0.947 
 
Table 11:  IR Spectra of Sitagliptin phosphate 
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Fig 14:  IR Spectra of HPMC E15 
 
 
No. Peak Intensity 
Corr. 
Intensity 
Base (H) Base (L) Area Corr. Area 
1 605.65 60.909 1.441 611.43 543.93 11.593 -0.046 
2 947.05 55.948 4.051 966.34 860.25 22.036 1.415 
3 1637.56 25.336 0.552 1651.07 1635.64 8.863 0.019 
4 3454.51 4.455 0.023 3462.22 3452.58 13.003 0.013 
 
Table 12:  IR Spectra of HPMC E15 
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Fig 15:  IR Spectra of HPMC E50 
 
 
No. Peak Intensity 
Corr. 
Intensity 
Base 
(H) 
Base (L) Area Corr. Area 
1 607.58 62.6036 1.6909 617.22 580.57 7.0633 0.1823 
2 947.05 69.2787 6.4461 968.27 864.11 11.9589 1.7804 
3 1633.71 26.4988 0.5196 1635.64 1627.92 4.3949 0.052 
4 3417.86 2.4373 0.4349 3431.36 3394.72 57.4735 1.3563 
 
Table 13 :  IR Spectra of HPMC E50 
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Fig 16:  IR Spectra of  Sitagliptin Phosphate  +  HPMC E15 
 
No. Peak Intensity 
Corr. 
Intensity 
Base (H) Base (L) Area Corr. Area 
1 509.21 47.35 9.618 518.85 478.35 9.733 1.195 
2 723.31 61.02 7.496 738.74 711.73 5.127 0.733 
3 1018.41 24.65 13.381 1037.7 997.2 20.677 3.675 
4 1151.5 15.266 19.575 1192.01 1114.86 47.294 11.445 
5 1276.88 30.095 17.342 1311.59 1259.52 19.707 3.575 
6 1338.6 41.608 14.362 1357.89 1311.59 14.661 2.943 
7 1429.25 28.691 9.694 1438.9 1392.61 17.337 0.844 
8 1517.98 16.845 28.864 1546.91 1487.12 31.57 11.253 
9 1668.43 19.401 13.906 1697.36 1649.14 27.051 4.454 
10 3421.72 10.728 0.854 3433.29 3143.97 222.048 -7.282 
 
Table 14:  IR Spectra of  Sitagliptin Phosphate  +  HPMC E15 
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Fig 17:  IR Spectra of  Sitagliptin Phosphate  +  HPMC E50 
 
No. Peak Intensity 
Corr. 
Intensity 
Base 
(H) 
Base (L) Area Corr. Area 
1 613.36 73.909 10.211 713.66 549.71 16.616 4.239 
2 723.31 58.154 4.755 1037.7 993.34 9.521 0.696 
3 1151.5 52.214 7.835 1192.01 1112.93 19.454 1.923 
4 1276.88 59.615 4.263 1311.59 1259.52 10.545 0.494 
5 1516.05 58.215 8.182 1541.12 1489.05 10.788 1.51 
6 1637.56 46.897 3.47 1653 1627.92 7.72 0.349 
7 3415.93 20.069 3.568 3442.94 3248.13 109.507 0.838 
 
Table 15:  IR Spectra of  Sitagliptin Phosphate  +  HPMC E50 
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Fig 18:  IR Spectra of sitagliptin Phosphate  +  HPMC E15 + HPMC E 50 
 
No. Peak Intensity 
Corr. 
Intensity 
Base (H) Base (L) Area Corr. Area 
1 613.36 76.445 10.358 680.87 549.71 11.719 3.618 
2 1020.34 60.974 5.393 1037.7 995.27 8.238 0.762 
3 1151.5 54.71 8.866 1192.01 1114.86 17.204 2.007 
4 1276.88 62.386 4.943 1311.59 1261.45 9.048 0.564 
5 1427.32 61.595 3.497 1438.9 1411.89 5.287 0.302 
6 1516.05 61.92 7.385 1539.2 1500.62 7.169 1.133 
7 1620.21 50.03 4.028 1627.92 1571.99 12.983 0.281 
8 1668.43 53.824 6.898 1699.29 1651.07 11.082 1.039 
9 3414 21.642 4.53 3442.94 3250.05 101.18 1.264 
 
Table 16:  IR Spectra of sitagliptin Phosphate  +  HPMC E15 + HPMC E 50
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8.4 EVALUATION PARAMETERS 
8.4.1 Thickness 
A micrometer screw gauge was used to measure the film thickness. In order to 
obtain uniformity of film, thickness is measured at 5 different locations. The 
thickness of the film should be less than 5 %. The thickness of fast dissolving  
films of all formulations given in table 17 and figure 19.  
8.4.2 Folding endurance 
To determine folding endurance, a film is cut and rapidly folded at the same place 
till it broke. The number of times the film could be folded at the same place 
without breaking gives the value of folding endurance. Topical folding endurance 
for film was between100-150. The folding endurance of fast dissolving films of 
all formulations given in table 17 and figure 19.  
8.4.3 Tensile strength 
Tensile strength is the maximum stress applied to a point at which the strip 
specimen breaks. It is calculated by the formula. 
Tensile strength =  Load at failure × 100___ 
   Strip thickness × strip width 
The tensile strength of fast dissolving films of all formulations given in table 17 
and figure 19.  
8.4.4 Percentage elongation  
It was calculated by 
Percentage elongation = Increase in length of strip × 100 
    Initial length of strip 
The percentage elongation of fast dissolving films of all formulations given in 
table 17 and figure 19.  
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 8.4.5 In-vitro disintegration 
Petri dish method 
2 ml of distilled water was placed in the petri dish and one film was added on the 
surface of water and the time measured until the oral film was dissolved 
completely.  
The in-vitro disintegration time of fast dissolving films of all formulations given 
in table 17 and figure 19.  
 
Table 17: Evaluation parameters 
Formulations 
Thickness 
(mm) 
Folding 
endurance 
Tensile 
strength 
(g/cm2) 
% 
elongation 
In-vitro 
disintegration 
time(sec) 
F1 0.58 9 48.41 8 25 
F2 0.55 10 51.18 9 28 
F3 0.59 13 62.04 11 20 
F4 0.51 9 54.25 9 31 
F5 0.53 11 53.68 10 35 
F6 0.52 11 52.33 8 27 
F7 0.55 12 56.45 7 36 
F8 0.57 1.0 57.62 9 32 
F9 0.53 9 48.63 10 35 
 
 
Fig 19: Bar chart of evaluation parameters 
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8.5 WEIGHT VARIATION 
8.5.1 Weight variation 
Ten films were randomly selected and their average weight was weighed. 
Individual films were weighed and compared with the average weight for the 
deviation. The weight variation of fast dissolving films of all formulations given 
in table 18 and figure 20.  
Table no 18: Weight Variation 
Formulations Weight variation (mg) 
F1 69 
F2 68 
F3 68.2 
F4 69.4 
F5 70.2 
F6 69.4 
F7 68.3 
F8 70.6 
F9 69.2 
 
 
 
 
 
 
 
Fig 20: Bar chart of weight variation 
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8.6 DRUG CONTENT AND ASSAY 
8.6.1 Drug content 
This test was performed by dissolving a 4 cm2 area of film in 50 ml of 0.1 N HCL 
with stirring. This solution was filtered using a whatmann filter paper, and the 
filtrate was diluted to 100 ml with the same buffer in a volumetric flask. This 
solution was analysed using UV spectrometer. The drug content result of all the 
formulations shown in table 19 and the values depicted as graphical representation 
in figure 21.  
8.6.2 ASSAY 
This test was performed by dissolving a 4 cm area of thin film in 50 ml of pH 6.8 
phosphate buffer with stirring. This solution was filtered using a Whatmann filter 
 paper, and the filtrate was diluted to 100 ml with the same buffer in a volumetric 
flask. This solution was analyzed using UV spectrophotometer. The assay result 
of all the formulations shown in table 19 and the values depicted as graphical 
representation in figure 21. 
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Table no 19: Drug content and Assay 
 
      Formulations Drug content (mg) Assay (%) 
F1 24.86 97.25 
F2 23.25 98.14 
F3 25.01 99.87 
F4 22.91 98.34 
F5 24.55 98.45 
F6 23.88 97.22 
F7 24.78 98.33 
F8 24.63 97.87 
F9 23.52 98.12 
 
 
Fig 21: Bar chart of drug content and assay 
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8.7 IN-VITRO DISSOLUTION 
 In-vitro dissolution 
900 ml of o.1 N HCL was used as a media, at was maintained at 37 +0.5 °c while 
the basket was set at 100 rpm. A film sample of 4 cm2 (2×2 cm) was cut and taken 
into the basket. 5 ml of the sample were taken every 2 minutes and the same 
amount was replaced with fresh 0.1 N HCL. The withdrawn samples were filtered 
and analyzed using a UV spectrometer at a wavelength of 267 nm. In-vitro 
dissolution profile data of all formulations given the table 20-28 and figure 22-30. 
The Percentage Cumulative Drug Release of F1 - F9 shown in table 29 Figure 31. 
The in-vitro dissolution profile data of marketed formulation depicted in table 30 
and figure 32. The comparison of in-vitro release data of marketed formulation 
and formulation 3 shown in table 31 and figure 33. 
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Table 20: In-vitro dissolution of F1 
Time 
(mins) 
Absorbance 
(267 nm) 
Concentration 
µg/ml 
Amount 
release 
mg/ml 
Cumulative 
amount 
release 
Cumulative 
percentage 
release 
0.5 0.043 4.134 18.60 18.6 19 
1.0 0.073 7.019 31.58 31.6 32 
1.5 0.121 11.63 52.35 52.4 52 
2.0 0.164 15.76 70.96 71.0 71 
2.5 0.193 18.65 83.94 84.0 84 
3.0 0.214 20.57 92.59 93.0 93 
 
 
 
Fig 22: In-vitro dissolution of F1 
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Table 21: In-vitro dissolution of F2 
 
Time 
(mins) 
Absorbance 
(267 nm) 
Concentration 
µg/ml 
Amount 
release 
mg/ml 
Cumulative 
amount 
release 
Cumulative 
percentage 
release 
0.5 0.049 4.71 21.20 21.2 21 
1.0 0.083 7.98 35.91 36.0 36 
1.5 0.135 12.98 58.41 58.4 58 
2.0 0.156 15.1 67.5 68.0 68 
2.5 0.198 19.03 85.67 86.0 86 
3.0 0.225 21.63 97.36 97.3 97 
 
 
Fig 23: In-vitro dissolution of F2 
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Table 22: In-vitro dissolution of F3 
 
Time 
(mins) 
Absorbance 
(267 nm) 
Concentration 
µg/ml 
Amount 
release 
mg/ml 
Cumulative 
amount 
release 
Cumulative 
percentage 
release 
0.5 0.050 4.807 17.30 17.3 17 
1.0 0.086 8.260 37.21 37.2 37 
1.5 0.100 9.611 43.26 43.3 43 
2.0 0.181 17.40 78.31 78.3 78 
2.5 0.220 21.15 82.21 82.2 82 
3.0 0.228 23.36 98.63 98.6 99 
 
 
 
Fig 24: In-vitro dissolution of F3 
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Table 23: In-vitro dissolution of F4 
 
Time 
(mins) 
Absorbance 
(267 nm) 
Concentration 
µg/ml 
Amount 
release 
mg/ml 
Cumulative 
amount 
release 
Cumulative 
percentage 
release 
0.5 0.052 5.01 22.54 23.0 23 
1.0 0.098 9.42 42.40 42.4 42 
1.5 0.134 12.88 58.10 58.1 58 
2.0 0.169 16.25 73.13 73.1 73 
2.5 0.188 18.07 81.35 81.3 81 
3.0 0.220 21.15 95.20 95.2 95 
 
 
Fig 25: In-vitro dissolution of F4 
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Table 24: In-vitro dissolution of F5 
Time 
(mins) 
Absorbance 
(267 nm) 
Concentration 
µg/ml 
Amount 
release 
mg/ml 
Cumulative 
amount 
release 
Cumulative 
percentage 
release 
0.5 0.053 5.09 22.93 23.0 23 
1.0 0.095 9.13 41.10 41.1 41 
1.5 0.124 11.9 53.65 54.0 54 
2.0 0.166 15.9 71.82 72.0 72 
2.5 0.182 17.5 78.85 79.0 79 
3.0 0.218 20.9 94.32 94.3 94 
 
 
Fig 26: In-vitro dissolution of F5 
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Table 25: In-vitro dissolution of F6 
Time 
(mins) 
Absorbance 
(267 nm) 
Concentration 
µg/ml 
Amount 
release 
mg/ml 
Cumulative 
amount 
release 
Cumulative 
percentage 
release 
0.5 0.049 4.71 21.20 21.2 21 
1.0 0.088 8.46 38.08 38.0 38 
1.5 0.132 12.7 57.16 57.2 57 
2.0 0.059 15.3 68.8 69.0 69 
2.5 0.194 18.7 83.9 84.0 84 
3.0 0.213 20.5 92.16 92.2 92 
 
 
Fig 27: In-vitro dissolution of F6 
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Table 26: In-vitro dissolution of F7 
Time 
(mins) 
Absorbance 
(267 nm) 
Concentration 
µg/ml 
Amount 
release 
mg/ml 
Cumulative 
amount 
release 
Cumulative 
percentage 
release 
0.5 0.048 4.62 20.76 20.8 21 
1.0 0.088 8.46 38.07 38.1 38 
1.5 0.128 12.31 55.39 55.4 55 
2.0 0.159 15.29 68.80 69.0 69 
2.5 0.189 18.17 81.77 82.0 82 
3.0 0.223 21.44 96.49 96.5 97 
 
 
 
Fig 28: In-vitro dissolution of F7 
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Table 27: In-vitro dissolution of F8 
Time 
(mins) 
Absorbance 
(267 nm) 
Concentration 
µg/ml 
Amount 
release 
mg/ml 
Cumulative 
amount 
release 
Cumulative 
percentage 
release 
0.5 0.039 3.75 16.88 16.9 17 
1.0 0.078 7.52 33.75 33.8 34 
1.5 0.134 12.88 57.98 58.0 58 
2.0 0.164 15.76 70.96 71.0 71 
2.5 0.190 18.27 82.21 82.2 82 
3.0 0.224 21.54 96.92 97.0 97 
 
 
Fig 29: In-vitro dissolution of F8 
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Table 28: In-vitro dissolution of F9 
Time 
(mins) 
Absorbance 
(267 nm) 
Concentration 
µg/ml 
Amount 
release 
mg/ml 
Cumulative 
amount 
release 
Cumulative 
percentage 
release 
0.5 0.046 4.42 19.90 19.9 20 
1.0 0.082 7.88 35.48 35.5 36 
1.5 0.140 13.46 60.58 60.6 61 
2.0 0.162 15.58 70.1 70.1 70 
2.5 0.186 17.88 80.5 81.0 81 
3.0 0.221 21.25 95.6 96.0 96 
 
 
 
 
Fig 30: In-vitro dissolution of F9 
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Table no 29: In-vitro dissolution of F1-F9 
Percentage drug released 
Time 
(min) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0.5 19 21 17 23 23 21 21 17 20 
1.0 32 36 37 42 41 38 38 34 36 
1.5 52 58 43 58 54 57 55 58 61 
2.0 71 68 78 73 72 69 69 71 70 
2.5 84 86 82 81 79 84 82 82 81 
3.0 93 97 99 95 94 92 97 97 96 
 
 
 
Fig 31: In-vitro dissolution of F1-F 
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8.8 In-vitro drug release profile data of marketed formulation 
 
Table no 30: in-vitro drug release profile data of marketed formulation 
Time 
(mins) 
Absorbance 
(267 nm) 
Concentration 
µg/ml 
Amount 
release 
mg/ml 
Cumulative 
amount 
release 
Cumulative 
percentage 
release 
10 0.038 3.65 16.44 16.4 16 
20 0.079 7.59 34.2 34.2 34 
30 0.110 10.58 47.6 48.0 48 
40 0.147 14.13 63.61 64.0 64 
50 0.178 17.16 77.02 77.0 77 
60 0.218 20.46 94.33 94.3 94 
 
 
Fig 32: in-vitro drug release profile data of marketed formulation 
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8.9 Comparison of in-vitro drug release data of marketed formulation and 
formulation 3 
Table no 31: Comparison of in-vitro drug release data of marketed 
formulation and formulation 3 
Time 
(mins) 
Absorbance 
(267 nm) 
Concentrati
on µg/ml 
Amount 
release 
mg/ml 
Cumulativ
e amount 
release 
Cumulative 
percentage 
release 
Cumulative 
percentage 
release of 
formulation 3 
10 0.038 3.65 16.44 16.4 16 17 
20 0.079 7.59 34.2 34.2 34 37 
30 0.110 10.58 47.6 48.0 48 43 
40 0.147 14.13 63.61 64.0 64 78 
50 0.178 17.16 77.02 77.0 77 82 
60 0.218 20.46 94.33 94.3 94 99 
 
 
Fig 33: Comparison of in-vitro drug release data of marketed formulation 
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and formulation 3 
8.10 STABILITY STUDIES (F3) 
The stability studies were carried out according to ICH to assess the drug 
formulation stability. Optimized F3 formulation was sealed in Aluminium packing 
laminated with polyethylene. Samples were kept at 40 c and 75% RH for 3 
months. At the end of study period, the formulation was observed for change in 
physical appearance, color, drug content and drug release characteristics. 
 
Table no 32: Stability studies [Condition (40°C/75%RH)] 
Parameters Initial 1 month 3 months 
Thickness (mm) 0.59 0.59 0.59 
Folding endurance 13 13 12 
Tensile strength (gm/cm2) 54.25 54.25 53.01 
in-vitro disintegration time (sec) 20 20 22 
in-vitro dissolution (%) 99.26 99.26 99.06 
 
Test frequency: Initial & 3 months 
• It is found to be all the physical and chemical parameters are satisfactory 
 based on initial stability data. 
• Photo stability studies have shown that the medicinal product is non-light 
 sensitive. 
 
 
 
 
Results and Discussions 
 
 
Cherraan’s College of Pharmacy 88 
 
8.11 SEM ANALYSIS 
The morphological study of oral strip was done by the scanning electron 
microscopy (SEM) at a definite magnification. Study refers the difference 
between upper and lower side of the films. It also helps in determination of the 
distribution of API. 
 
 
Fig 34 : SEM images 
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Fig 35: SEM images 
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8.12 DISCUSSION 
 
The present investigation was undertaken to formulate Sitagliptin phosphate oral 
films. For the treatment of Diabetes mellitus. 
F1-F3 were carried out with HPMC E15 cps, PEG 400, sodium saccharin, citric 
acid and flavor. The films were clear and transparent. The thickness also uniform. 
The flexibility also good. The films shown good mechanical properties. According 
to the assay result the drug was properly loaded in the film.  
F4-F6 were carried out with HPMC E50, propylene glycol, sodium saccharin, 
citric acid and flavor. The films shows good appearance. The thickness also not 
uniform. The flexibility of the film was not good. The percentage drug release was 
found to be. 
F7 was formulated with HPMC E15, propylene glycol, sodium saccharin, citric 
acid and flavor. The appearance of the film was also good but the thickness and 
disintegration time was more. 
F8 was formulated with HPMC E50, PEG 400, sodium saccharin, citric acid and 
flavor.  
F9 was formulated with HPMC E15 & E50 without the addition of plasticizers. 
The formulated films were more brittleness.  
Among all the formulations F3 shown good mechanical properties and less 
disintegration time of 20 seconds. All the parameters of film were found to be 
satisfactory. And the dissolution profile was found to be desirable and 
reproducible. 
The morphological study (SEM) of F3 shows more porous. Therefore rapid drug 
release was achieved for the immediate onset of action. 
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The stability studies were performed for about 1 month and 3 months. No 
significant changes were observed in the thickness, tensile strength, in-vitro 
disintegration and in-vitro drug release. 
The film (F3) samples evaluated gave maximum release within 3 minutes 
indicating the rapid drug release profile which entails in faster onset of action for 
the medicament. Therefore the oral films have considerable advantage over the 
conventional dosage forms. 
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9.  SUMMARY AND CONCLUSION 
 
The primary objective of this work was to develop a mouth dissolving film with 
Sitagliptin phosphate, along with basic ingredients like polymers, plasticizers, 
sweetener, saliva stimulating agent and flavor. 
The films were prepared by solvent casting method. 
HPMC E50 cps, which was not able to impart thickness to the film. HPMC E15 
shown good flexibility.  
The plasticizer propylene glycol which was not able to impart flexibility and 
folding endurance to the film. PEG 400 produced good folding endurance, tensile 
strength and percent elongation. 
The optimized formulation (F3) was shown good mouth feel, folding endurance, 
instant drug release as well as good mechanical properties. 
The F3, shown less disintegration time of 20 seconds and 99% drug released 
within 3 minutes while the marketed formulation took 1 hour. 
Therefore rapid drug release was achieved for immediate onset of action which is 
beneficial when compared to conventional tablet dosage form.  
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